ImmunoCellular Therapeutics, Ltd' Brain Cancer Technology Receives Important Japanese Patent Allowance  
7/10/2012 10:13:50 AM

S ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular Therapeutics” or the Company”) (NYSE MKT: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license. The patent covers the treatment of brain cancer with a combination of a dendritic cell based vaccine combined either before or concurrently with the administration of chemotherapy. The Company believes that in the treatment of cancer, particularly cancers of the central nervous system such as glioblastoma multiforme (GBM), a dual therapeutic approach that includes the administration of a dendritic cell-based cancer vaccine combined with a regimen of chemotherapy could substantially enhance the clinical efficacy of treatment.